fashion -WSS

fashion

author：comprehensive 2025-10-02 21:00:25 - browse：41

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

WSS

Medicare Advantage insurers pressure Biden for bigger payments

Crowdfunding for unproven stem cell procedures spreads misinformation

Security flaws in third

Pregnancy ages women, but effects reverse after delivery

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Use doctors trained outside the U.S. to ease the physician shortage

explore

fashion

focus

In Memoriam: Notable people who died in 2023

Being 'nonadherent' patient made me a more empathetic doctor

Activists slam private health insurers over coverage restrictions

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Apple is now the first public company to be valued at $3 trillion

Crowdfunding for unproven stem cell procedures spreads misinformation

Anesthesiologist group: stop taking Ozempic before surgery

Pfizer, Moderna say biotech, pharma drug development is a sprint

Virginia high school admissions case could be legal follow

The biotech scorecard for Q3: 15 stock

explore

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Fatty liver disease was alleviated by Lilly’s ‘triple

'Screen and refer' systems are hurting patients

Drug cartel violence flares in western Mexico after vigilante leader's killing

Canadians with cystic fibrosis outlive Americans by a decade

knowledge

knowledge

entertainment

leisure time